

## **Supplementary Table legends**

### **Table S1. List of primer sequences for qRT-PCR.**

## **Supplementary Figure legends**

### **Figure S1. Cytotoxicity of bestatin measured by cell viability assay in BHK-21, LF-BK, ZZ-R, murine PECs and porcine PBMCs.**

(a–e) Cell viability of BHK-21 (a); LF-BK (b), ZZ-R cells (c); murine PECs (d); and porcine PBMCs (e).

Data have been represented as the mean  $\pm$  SEM of triplicate measurements ( $n = 3$ /group).

Statistical analyses were performed using one-way ANOVA with Dunnett's *post hoc* test.

### **Figure S2. Bestatin alone-mediated host defense in early stage of FMDV infection on mice.**

C57BL/6 mice (6–7 weeks-old,  $n = 5$ /group) were administered intramuscularly a bestatin alone. Mice were challenged with FMDV O (100 LD<sub>50</sub> O/VET/2013) or FMDV A (100 LD<sub>50</sub> A/Malay/97) at 3 or 7 days post-injection (dpi) using an intraperitoneal injection. Survival rates and body weights were monitored for 7 days post-challenge (dpc) with the respective viruses. (a–i) experimental workflow (a); survival rates in 3 dpi challenged group with O/VET/2013 (b) or A/Malay/97 (c); changes in body weight 3 dpi challenged group with O/VET/2013 (d) or A/Malay/97 (e); survival rates in 7 dpi challenged group with O/VET/2013 (f) or A/Malay/97 (g); and changes in body weight 7 dpi challenged group with O/VET/2013 (h) or A/Malay/97 (i). Data are presented as mean  $\pm$  SEM of triplicate measurements ( $n = 5$ /group).

**Table S1**

Target	Forward/Reverse	Sequence (5-3)	Length(mer)
IFN $\alpha$	IFN $\alpha$ F	CATCTGCTCTCTGGGCTGTG	20
	IFN $\alpha$ R	TGAGGGGATCCAAAGTCCCT	20
IFN $\beta$	IFN $\beta$ F	TGCAACCACCACAATTCCAGA	21
	IFN $\beta$ R	GGTTTCATTCCAGCCAGTGC	20
IFN $\gamma$	IFN $\gamma$ F	GCCATTCAAAGGAGCATGGAT	21
	IFN $\gamma$ R	CTGATGGCTTTGCGCTGGAT	20
IL-29	IL-29 F	GCTACAGCTTGGATCGTGGT	20
	IL-29 R	TCAGGTCCCTTACGAGGAGG	20
RIG-I	RIG-I F	GCACCTCATACTTACAGCCCA	21
	RIG-I R	CCACAACCAGTAGGAGCACAT	21
CD28	CD28 F	TCAAAGGAGTTCCGGGCATC	20
	CD28 R	CTGAAGCAGGCGGGAGTAAT	20
CD19	CD19 F	GCAGGTCCTCTTCCAGTCAC	20
	CD19 R	TCAGGATCAGGGCTCTTCGA	20
CD21	CD21 F	TGCCATGCCTACAAAGCTGA	20
	CD21 R	GTAGTAACCAGGGCGGCATT	20
CD81	CD81 F	CCAGACTACCAGCCTCCTCT	20
	CD81 R	GCACAGTACCATGCTCAGGA	20
C3d	C3d F	ACAAATTGACCCAGCGTAGG	20
	C3d R	GCACGTCCTTGCTGTACTGA	20
HPRT	HPRT F	CCCAGCGTCGTGATTAGTGA	20
	HPRT R	GCCGTTCAAGTCCTGTCCATA	20

Figure S1




Figure S2

(a)




Figure S2 (continued)




Figure S2 (continued)

